Trimethylammonium

Trimethylammonium

SCHEMBL2226422

CCCC=CCCCCCCCCCCCCCCCC.CN(C)C

nearest known ligand 0.58

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 4/20 0.58
TRPV1 Q8NER1 1/20 0.58
TERT O14746 3/20 0.50
PTPN1 P18031 3/20 0.50
PPARG P37231 3/20 0.50
PPARD Q03181 3/20 0.50
PPARA Q07869 3/20 0.50
CYP1A2 P05177 2/20 0.50
MAPT P10636 2/20 0.50
CYP2C19 P33261 2/20 0.50
BLM P54132 2/20 0.50
HSD17B10 Q99714 2/20 0.50
FABP4 P15090 2/20 0.50
KMT2A Q03164 2/20 0.50
TOP1 P11387 2/20 0.50
GMNN O75496 1/20 0.50
USP2 O75604 1/20 0.50
LMNA P02545 1/20 0.50
POLB P06746 1/20 0.50
CYP2C9 P11712 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trimethylammonium SCHEMBL26623150 0.95 FAAH (0.64) FAAHTRPV1TERTPTPN1PPARG
Trimethylammonium SCHEMBL4450279 0.95 FAAH (0.64) FAAHTRPV1TERTPTPN1PPARG
SCHEMBL5853539 0.92 FAAH (0.67) FAAHTRPV1TERTPTPN1PPARG
SCHEMBL5855889 0.92 FAAH (0.67) FAAHTRPV1TERTPTPN1PPARG
SCHEMBL2837920 0.92 FAAH (0.67) FAAHTRPV1TERTPTPN1PPARG
SCHEMBL514736 0.92 FAAH (0.67) FAAHTRPV1TERTPTPN1PPARG
SCHEMBL5854970 0.92 FAAH (0.67) FAAHTRPV1TERTPTPN1PPARG
SCHEMBL454819 0.92 FAAH (0.67) FAAHTRPV1TERTPTPN1PPARG
SCHEMBL20584432 0.92 FAAH (0.67) FAAHTRPV1TERTPTPN1PPARG
SCHEMBL5855886 0.92 FAAH (0.67) FAAHTRPV1TERTPTPN1PPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4294450-A1 METHODS FOR PREPARATION OF PLASMID DNA/LIPID PARTICLES WITH DEFINED SIZE FOR IN VITRO AND IN VIVO TRANSFECTION The Johns Hopkins University (US) 2023-12-27 EP claimed
WO-2023119222-A1 METHOD FOR THE PREPARATION OF HYBRID POLYMERIC NANOPARTICLES FOR THE RELEASE OF OLIGONUCLEOTIDE DRUGS IN PHARMACOLOGICAL THERAPIES FOR REGENERATIVE, CURATIVE, AND PREVENTIVE PURPOSES POLITECNICO DI TORINO (IT) 2023-06-29 WO claimed
WO-2023064907-A1 COMPOSITIONS AND METHODS FOR VACCINATION AGAINST PATHOGENIC CORONAVIRUS SPECIES AND VARIANTS YALE UNIVERSITY (US) 2023-04-20 WO claimed
EP-3697384-A1 PREPARATION AND STORAGE OF LIPOSOMAL RNA FORMULATIONS SUITABLE FOR THERAPY BioNTech RNA Pharmaceuticals GmbH (DE) 2020-08-26 EP claimed
WO-2019077053-A1 PREPARATION AND STORAGE OF LIPOSOMAL RNA FORMULATIONS SUITABLE FOR THERAPY BIONTECH RNA PHARMACEUTICALS GMBH (DE) 2019-04-25 WO claimed
WO-2018204421-A2 MOMP TELONANOPARTICLES, AND RELATED COMPOSITIONS, METHODS AND SYSTEMS LAWRENCE LIVERMORE NATIONAL SECURITY, LLC (US) 2018-11-08 WO claimed
EP-3277263-A1 LIPID PARTICLE FORMULATIONS FOR DELIVERY OF RNA AND WATER-SOLUBLE THERAPEUTICALLY EFFECTIVE COMPOUNDS TO A TARGET CELL BioNTech RNA Pharmaceuticals GmbH (DE) 2018-02-07 EP claimed
WO-2016156398-A1 LIPID PARTICLE FORMULATIONS FOR DELIVERY OF RNA AND WATER-SOLUBLE THERAPEUTICALLY EFFECTIVE COMPOUNDS TO A TARGET CELL BIONTECH RNA PHARMACEUTICALS GMBH (DE) 2016-10-06 WO claimed
WO-2016155809-A1 LIPID PARTICLE FORMULATIONS FOR DELIVERY OF RNA AND WATER-SOLUBLE THERAPEUTICALLY EFFECTIVE COMPOUNDS TO A TARGET CELL BIONTECH RNA PHARMACEUTICALS GMBH (DE) 2016-10-06 WO claimed
EP-3049065-A1 PARTICLES COMPRISING A SHELL WITH RNA BioNTech AG (DE) 2016-08-03 EP claimed
EP-2968586-A2 CFTR MRNA COMPOSITIONS AND RELATED METHODS AND USES Shire Human Genetic Therapies, Inc. (US) 2016-01-20 EP claimed
EP-2972360-A1 SYNERGISTIC ENHANCEMENT OF THE DELIVERY OF NUCLEIC ACIDS VIA BLENDED FORMULATIONS Shire Human Genetic Therapies, Inc. (US) 2016-01-20 EP claimed
WO-2014153052-A9 CFTR MRNA COMPOSITIONS AND RELATED METHODS AND USES SHIRE HUMAN GENETIC THERAPIES, INC. (US) 2015-08-06 WO claimed
WO-2015043613-A1 PARTICLES COMPRISING A SHELL WITH RNA BIONTECH AG (DE) 2015-04-02 WO claimed
WO-2014153052-A2 CFTR MRNA COMPOSITIONS AND RELATED METHODS AND USES SHIRE HUMAN GENETIC THERAPIES, INC. (US) 2014-09-25 WO claimed
WO-2014144196-A1 SYNERGISTIC ENHANCEMENT OF THE DELIVERY OF NUCLEIC ACIDS VIA BLENDED FORMULATIONS SHIRE HUMAN GENETIC THERAPIES, INC. (US) 2014-09-18 WO claimed
WO-2014047329-A1 METHODS FOR USING LIPID PARTICLES NDSU RESEARCH FOUNDATION (US) 2014-03-27 WO claimed
WO-2011089595-A2 SUSTAINED-RELEASE NUCLEIC ACID MATRIX COMPOSITIONS POLYPID LTD. (IL) 2011-07-28 WO claimed
EP-4398882-A1 LIPID-BASED RNA FORMULATIONS SUITABLE FOR THERAPY BioNTech SE (DE) 2024-07-17 EP disclosed
WO-1999047678-A2 INTERFERON ALPHA PLASMIDS AND DELIVERY SYSTEMS, AND METHODS OF MAKING AND USING THE SAME VALENTIS, INC. (US) 1999-09-23 WO disclosed